Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Jacobio Pharmaceuticals Group Co., Ltd. ( (HK:1167) ) has issued an update.
Jacobio Pharmaceuticals Group Co., Ltd. has scheduled a board meeting for March 10, 2026, to review and approve the annual results for the year ended December 31, 2025, and to authorize their publication. The meeting signals the forthcoming disclosure of the company’s financial and operational performance, a key event for investors and other stakeholders monitoring its progress in the pharmaceutical sector.
The board, led by Chairman and executive director Dr. Yinxiang Wang and comprising executive, non-executive and independent non-executive directors, will also address any other business at the meeting. This governance step underscores the company’s adherence to Hong Kong listing requirements and provides a timeline for the market to anticipate updated financial information and strategic developments.
The most recent analyst rating on (HK:1167) stock is a Sell with a HK$5.00 price target. To see the full list of analyst forecasts on Jacobio Pharmaceuticals Group Co., Ltd. stock, see the HK:1167 Stock Forecast page.
More about Jacobio Pharmaceuticals Group Co., Ltd.
Jacobio Pharmaceuticals Group Co., Ltd. is a Hong Kong-listed biopharmaceutical company focused on developing and commercializing pharmaceutical products. The group operates through its subsidiaries and is governed by a board comprising executive, non-executive and independent non-executive directors, reflecting a typical corporate governance structure for a listed pharma company.
Average Trading Volume: 4,543,257
Technical Sentiment Signal: Hold
Current Market Cap: HK$4.87B
Find detailed analytics on 1167 stock on TipRanks’ Stock Analysis page.